CbpM and CbpG of Streptococcus Pneumoniae Elicit a High Protection in Mice Challenged with a Serotype 19F Pneumococcus.
This study aims to determine the immunogenicity of CbpM, CbpG and CbpL proteins of Streptococcus pneumoniae in a mice model. The genes were cloned into pET21a expression vector and the recombinant proteins were produced. Mice were immunized with the purified recombinant proteins. Subsequently, the mice were challenged with S. pneumoniae ATCC 49619 (2×106 CFU) and their survival and bacterial clearances were followed 24 hours after infection. The antibody responses of the mice were determined by ELISA assay. The opsonophagocytosis assay was performed using rabbit's sera. Passive immunization was carried out using two doses of anti-CbPs antibodies. Finally, these mice were experimentally infected with virulent bacteria and the protective effects of two doses of 10 and 100 µg/mL by monitoring the survival rate and bacterial clearance were determined at 2, 3 and 7 days after bacterial challenge. The mice actively immunized with CbpM, CbpG and CbpL recombinant proteins showed survival rate of 100%, 85% and 75%, respectively. The survival rates among passively immunized mice groups which received 100 µg/mL dose of anti-CbpM, anti-CbpG and anti- CbpL were 50%, 50% and 25%, respectively. The rates of opsonization with rabbit's antibodies against CbpM, CbpG, and CbpL at 100 µg/mL doses was 45.6%, 14.7% and 82.3%, and at 10 µg/mL was 12.9%, 12.2% and 9.35%, respectively. Our findings suggest that the recombinant proteins particularly CbpM ...
Introduction: Atopic dermatitis (AD) is a chronic, inflammatory and pruritic skin disease, with a prevalence of 1-3% of the adult population. Usually begins in early childhood, progresses with a recurrent course before disappearing at puberty, and may persist to adulthood or present de novo during this period. It is frequently associated with elevated levels of serum IgE, individual or family history of type I allergies, allergic rhinitis and asthma. The therapeutic approach in adult AD patients can be frankly complicated beyond topical treatments, as phototherapy and/or systemic therapies often do not guarantee adequate c...
AbstractBackgroundBlood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO) concentration are established biomarkers in asthma, associated particularly with the risk of exacerbations. We evaluated the relationship of BEC and FeNO as complementary and independent biomarkers of severe asthma exacerbations.MethodsThis observational study included data from the Optimum Patient Care Research Database. Asthma patients (18 –80 years) with valid continuous data for 1 year before FeNO reading, ≥ 1 inhaled corticosteroid prescription, and BEC recorded ≤ 5 years bef...
Peanut allergy is a generally persistent, sometimes life-threatening food allergy that is increasing in prevalence in Western countries.1 There are no FDA-approved therapies for treatment of peanut allergy, and patients must strictly avoid peanut and be prepared to use rescue medication upon symptoms due to unintentional peanut ingestion.1 However, complete avoidance of peanut is difficult at least in part due to its widespread use as a food ingredient in packaged foods and in restaurant or catered meals.
ConclusionsThe benefits of FENO-based management are attenuated among obese mothers and those with excess GWG, indicating the importance of weight management in contributing to improved asthma management in pregnancy.
In Project Viva, a pre-birth cohort study, we identified potential protective prenatal nutrients (Vitamin D, n-3 PUFAs), as well as adverse prenatal pro-oxidant exposures that may alter risk of asthma and allergic disease into adolescence.
Febrile lower respiratory infections trigger uniquely potent/complex immunoinflammatory responses in infants, which enhance both immune maturation and asthma development. Characterization of underlying fever-associated transcriptomic profiles may unmask previously hidden clues regarding mechanisms driving asthma initiation.
This article explores the most relevant issues facing the role of e-Health and its sub-category—mobile health (mHealth)—in promoting treatment adherence in childhood asthma, focusing on current evidence gaps and limitations, and future research perspectives.
ConclusionsPrognosis in patients with CRSwNP was inferior to that in patients with CRSsNP. Asthma was the only factor that increased the chance of recurrence in patients with either CRSsNP or CRSwNP.
This study supports a positive benefit-risk profile for long-term mepolizumab treatment in these patients.